EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world use of cefiderocol for the treatment of metallo-β-lactamase-producing Gram-negative infections: A subgroup analysis of the PERSEUS study

Carmen Hidalgo-Tenorio, Lucía García Labrador, A. Javier González Calvo, Belén Loeches Yagüe

Enfermedades Infecciosas y Microbiología Clínica · 2027-01 · 45 (1) · 503364

DOI: 10.1016/j.eimc.2026.503364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Enfermedades Infecciosas y Microbiología Clínica, 2027-01. Verfasst von Carmen Hidalgo-Tenorio und 3 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi and Co Ltd.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Infections caused by metallo-β-lactamase (MBL)-producing Gram-negative bacteria pose a major therapeutic challenge due to extensive antimicrobial resistance. Cefiderocol, a siderophore cephalosporin, has shown promising in vitro activity against these pathogens.

Methods

This retrospective subgroup analysis of the PERSEUS study evaluated adult patients in Spain with confirmed MBL-producing Gram-negative infections treated with cefiderocol under the early access program.

Results

Among 98 patients, predominantly critically ill, clinical cure was achieved in 86.7% ( n = 85), and 28-day mortality was 18.4% ( n = 18). Clinical success was 88.8% ( n = 87), with similar outcomes in Pseudomonas aeruginosa (90.4%; n = 66) and Enterobacterales (90.0%; n = 9). Cefiderocol was mainly used as monotherapy and it was well tolerated.

Conclusions

Cefiderocol demonstrated high clinical effectiveness and a favorable safety profile in treating severe MBL-producing Gram-negative infections, supporting its role as a valuable option in high-risk patients with limited alternatives.

Förderung

  • Shionogi and Co Ltd

Zitieren

APA

Hidalgo-Tenorio, C., Labrador, L. G., Calvo, A. J. G., & Yagüe, B. L. (2027). Real-world use of cefiderocol for the treatment of metallo-β-lactamase-producing Gram-negative infections: A subgroup analysis of the PERSEUS study. Enfermedades Infecciosas y Microbiología Clínica, 45(1), 503364. https://doi.org/10.1016/j.eimc.2026.503364

Vancouver

Hidalgo-Tenorio C, Labrador LG, Calvo AJG, Yagüe BL. Real-world use of cefiderocol for the treatment of metallo-β-lactamase-producing Gram-negative infections: A subgroup analysis of the PERSEUS study. Enfermedades Infecciosas y Microbiología Clínica. 2027;45(1):503364. doi:10.1016/j.eimc.2026.503364

BibTeX
@article{HidalgoTenorio2027,
  author = {Hidalgo-Tenorio, Carmen and Labrador, Lucía García and Calvo, A. Javier González and Yagüe, Belén Loeches},
  title = {Real-world use of cefiderocol for the treatment of metallo-β-lactamase-producing Gram-negative infections: A subgroup analysis of the PERSEUS study},
  journal = {Enfermedades Infecciosas y Microbiología Clínica},
  year = {2027},
  volume = {45},
  number = {1},
  pages = {503364},
  doi = {10.1016/j.eimc.2026.503364}
}
Kostenlos starten →